Perrine Devic
YOU?
Author Swipe
View article: Phenotype–genotype correlation in X‐linked Charcot‐Marie‐Tooth disease: A French cohort study
Phenotype–genotype correlation in X‐linked Charcot‐Marie‐Tooth disease: A French cohort study Open
Background and purpose X‐linked Charcot‐Marie‐Tooth disease type 1 (CMTX1) ranks as the second most prevalent hereditary neuropathy and, currently, has no definitive cure. Emerging preclinical trials offer hope for potential clinical studi…
View article: Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma
Mononeuritis multiplex following immune checkpoint inhibitors in malignant pleural mesothelioma Open
Introduction Mononeuritis multiplex is frequently related to vasculitic neuropathy and has been reported only sporadically as an adverse event of immune checkpoint inhibitors. Methods Case series of three patients with mononeuritis multipl…
View article: Clinical and electrophysiological characteristics of women with X‐linked Charcot–Marie–Tooth disease
Clinical and electrophysiological characteristics of women with X‐linked Charcot–Marie–Tooth disease Open
Background X‐Linked Charcot–Marie–Tooth disease type 1 (CMTX1) is characterized by gender differences in clinical severity. Women are usually clinically affected later and less severely than men. However, their clinical presentation appear…
View article: Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity Open
While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients’ outcomes are not well documented. This study aimed to assess outcomes of neurological immune-related adverse events and to identi…
View article: P11.66.A Immune checkpoint inhibitors related peripheral nerve disorders: clinical and electrophysiological particularities
P11.66.A Immune checkpoint inhibitors related peripheral nerve disorders: clinical and electrophysiological particularities Open
Background The immune-checkpoint inhibitors (ICIs) announced a new era in cancer treatment allowing long-term survival in advanced cancers. However, immune related adverse events impose treatment limitations being one of the main challenge…
View article: Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors Open
Myelitis is a rare but severe complication of ICIs that shows limited response to glucocorticoids. Considering the poor functional outcome associated with longitudinally extensive myelitis, strong and protracted immune therapy combinations…
View article: Description of neurotoxicity in a series of patients treated with CAR T-cell therapy
Description of neurotoxicity in a series of patients treated with CAR T-cell therapy Open
Chimeric antigen receptor-modified T (CAR T) cell therapy is a highly promising treatment for haematological malignancies but is frequently associated with cytokine release syndrome and neurotoxicity. Between July 2018 and July 2019, all p…
View article: Commercial <scp>anti‐CD19 CAR</scp> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Commercial <span>anti‐CD19 CAR</span> T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center Open
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). …
View article: Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature
Guillain-Barré Syndrome During Platinum-Based Chemotherapy: A Case Series and Review of the Literature Open
Platinum-based chemotherapy is commonly associated with toxic sensory neuropathies, but also, although rarely, with Guillain-Barré syndrome (GBS). We describe five patients who developed GBS while receiving platinum-based chemotherapy for …